This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CDX-313, CDX 313, Captisol-Enabled Budesonide/Azelastine
Description: Budesonide/Azelastine is a nasal spray formulation of budesonide (a glucocorticoid steroid) and azelastine. Budesonide/Azelastine incorporates CyDex's patented Captisol technology.
Deal Structure: Budesonide/Azelastine was developed by CyDex.
In January 2011, Ligand acquired CyDex Pharmaceuticals.Ligand and RODES
In December 2015, RODES and Ligand Pharmaceuticals announced the signing of exclusive global license and supply agreements for three Captisol-enabled (CE) programs. Under the terms of the agreements, for each program Ligand will be eligible to receive development and commercial milestone payments, revenue from the sales of Captisol, and royalties of 8% to 11% on future net sales. RODES will be responsible for all costs related to the development and commercialization of the programs.
Partners: Ligand Pharmaceuticals, Inc.
Pink Sheet FDA’s ANDA Approvals
Pink Sheet May ANDA Approvals
Additional information available to subscribers only: